Soligenix, Inc. (SNGX)

Over the past six months, Soligenix's stock (SNGX) has declined by approximately 36.72%, with a stock price of $1.14 per share as of April 9, 2026, representing a 39.04% decline over the past year. Key events include the announcement of 2025 financial results with no revenues and a net loss of $11.1 million, Q3 2025 results highlighting HyBryte™ Phase 3 progress, positive clinical results from a HyBryte™ comparative study, Orphan Drug Designation from the European Commission for SGX945, and Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency for SGX945.

Information regarding direct demand seasonality for Soligenix's specific products and services is not explicitly detailed. Demand is likely driven by disease prevalence, clinical trial outcomes, regulatory approvals, and government funding rather than typical seasonal consumer patterns. Historically, July has shown the highest probability of positive returns for SNGX stock, while April and May may not be ideal months for stock investment. This seasonality pertains to investor demand for the stock rather than direct product demand.

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases with unmet medical needs, operating in the Pharmaceuticals: Major industry. Its business is divided into Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment includes HyBryte™ (SGX301) for cutaneous T-cell lymphoma, SGX302 for psoriasis, and SGX942/SGX945 (dusquetide) for oral mucositis and aphthous ulcers. The Public Health Solutions segment focuses on vaccine and biodefense programs, including RiVax® for ricin toxin, SGX943 for antibiotic-resistant diseases, ThermoVax® heat stabilization platform, and CiVax™ for COVID-19.

Soligenix, Inc. is headquartered in Princeton, New Jersey, United States, focusing on developing and commercializing products to treat rare diseases in the United States. Its products have also received regulatory designations in Europe and the UK, indicating a broader potential market.

Soligenix's brand reputation has been positively influenced by progress in its clinical programs and regulatory achievements. Positive events include the publication of positive clinical results for HyBryte™ in a comparative study against Valchlor®, receipt of Orphan Drug Designation from the European Commission for SGX945, SGX945 receiving Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency, announcement of a HyBryte™ clinical summary published in "Expert Opinion on Investigational Drugs", recognition of HyBryte™ receiving orphan drug and fast track designations, publication of positive clinical results from the Phase 2 trial of SGX945, and announcement of top-line results from the Phase 2a study of SGX302.

Soligenix, Inc. has a mix of institutional, retail, and individual investors. Institutional investors own approximately 1.61% to 3.60% of the stock, insiders hold about 3.86%, and the general public holds around 93.31%. Major institutional shareholders include DRW Securities, LLC, Vanguard Group Inc, and Geode Capital Management, Llc. Armistice Capital LLC, Connective Capital Management LLC, and Two Sigma Investments LP have been among the institutional investors buying Soligenix's stock in the last 24 months.